

Gerontological Advanced Practice Nurses Association (GAPNA) Virtual Product Theater Sponsored by ACADIA Pharmaceuticals Inc.

A Long-Term Care Resident With Hallucinations and Delusions Associated With Parkinson's Disease Psychosis: A Case for NUPLAZID

Wednesday, August 26, 2020

8:00 - 9:00 pm ET

Thursday, August 27, 2020

1:00 - 2:00 pm ET

See Indication and Important Safety Information including **Boxed WARNING** below. Please read the full [Prescribing Information](#), including **Boxed WARNING**, also available at NUPLAZIDhcp.com.

Indication

NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Important Safety Information for NUPLAZID (pimavanserin)

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

- **Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.**
- **NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson's disease psychosis.**
- **Contraindication:** NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.
- **QT Interval Prolongation:** NUPLAZID prolongs the QT interval.
 - The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics.

- NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.

- **Adverse Reactions:** The most common adverse reactions ($\geq 2\%$ for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs $<1\%$).

• **Drug Interactions:**

- Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.
- Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.

Dosage and Administration

Recommended dose: 34 mg capsule taken orally once daily, without titration.

NUPLAZID is available as 34 mg capsules and 10 mg tablets.

Please read the full [Prescribing Information](#), also available at NUPLAZIDhcp.com.

©2020 ACADIA Pharmaceuticals Inc. ACADIA and NUPLAZID are registered trademarks of ACADIA Pharmaceuticals Inc. All rights reserved. NU-1781 03/20.

ONCE-DAILY
NUPLAZID[®]
(pimavanserin) 34mg capsules

A Long-Term Care Resident With Hallucinations and Delusions Associated With Parkinson's Disease Psychosis: A Case for NUPLAZID

FACULTY



Kaylee Mehlman, PharmD, RPh, BCGP
Independent Clinical Consultant Pharmacist
PharmaSenior Consulting LLC



Gustavo Alva, MD, DFAPA
Medical Director, ATP Clinical Research
Assistant Professor, University of California Riverside
Department of Psychiatry and Neuroscience

LOCATION

[Click here to register for the August 26 program](#)

[Click here to register for the August 27 program](#)

LEARNING OBJECTIVES

Discuss educational information about hallucinations and delusions associated with Parkinson's disease (PD) psychosis, including:

- The symptoms of PD psychosis, a non-motor aspect of PD
- The impact and burden of PD psychosis on patients and their caregivers
- The proposed role of serotonin, specifically 5-HT_{2A} receptors, in PD psychosis
- The relevant treatment considerations when addressing PD psychosis

Review the clinical efficacy data and safety profile of NUPLAZID 34mg, the first and only FDA-approved treatment for delusions and hallucinations associated with PD psychosis

Sponsored by



Indication

NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Important Safety Information for NUPLAZID (pimavanserin)

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
- NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson's disease psychosis.

See additional Important Safety Information on reverse. Please read the full [Prescribing Information](#), including **Boxed WARNING**, also available at NUPLAZIDhcp.com.

ONCE-DAILY
NUPLAZID[®]
(pimavanserin) 34mg capsules